Skip to main content

Market Overview

Johnson & Johnson To Pay $300M In Punitive Damages In Olson Talc Cancer Case

Share:
Johnson & Johnson To Pay $300M In Punitive Damages In Olson Talc Cancer Case

Johnson & Johnson (NYSE: JNJ) has been ordered by a jury to pay $300 million in punitive damages to a woman who blamed her rare asbestos-related cancer on the company’s talc products.

The plaintiff is Donna Olson, who has mesothelioma in her lungs. Bloomberg said Johnson & Johnson faces more than 14,000 claims that its talc powder caused ovarian cancer and mesothelioma, a rare cancer linked to asbestos exposure.

Trials over the cancer claims tied to Johnson & Johnson’s talc-based powders first began in 2016. This New York verdict was the 10th win for talc plaintiffs.

A company spokesperson told Reuters the talc trial had "significant legal and evidentiary errors" which the company believes will warrant reversal amid appeal.

Johnson & Johnson's stock fell sharply following the news, but quickly rebounded. Shares traded around $131.07 at time of publication.

Related Links:

Analysts View Johnson & Johnson's Organic Growth Guidance As Conservative

Johnson & Johnson's Asbestos Woes: Experts Speak Up

Photo credit: Austin Kirk, Flickr

 

Related Articles (JNJ)

View Comments and Join the Discussion!

Posted-In: TalcNews Legal Media Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com